Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

Ultimate Outcomes of Patients with Recurrent Diffuse Large B Cell Lymphoma Who Do Not Respond to Second-Line Chemotherapy

Rebecca Elstrom, MD, Peter Martin, Katya Ostrow, Jacqueline Barrientos, Richard R. Furman, Jia Ruan, Michael Schuster, Tsiporah Shore, Amy Chadburn, Morton Coleman, MD, John P. Leonard, MD

Blood (2008) 112 (11): 4940.

https://doi.org/10.1182/blood.V112.11.4940.4940

Published: 2008

Journal Articles

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Blood (2008) 111 (3): 1101–1109.

https://doi.org/10.1182/blood-2007-05-090258

Published: 2008

Includes: Supplemental data

Journal Articles

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Tomer Mark, MD, David Jayabalan, Roger N. Pearse, MD/PhD, Jessica Stern, Jessica Furst, April Rambo, RN, John Harpel, MD/PhD, Tsiporah Shore, MD, Michael Schuster, MD, John P. Leonard, MD, Paul J. Christos, MPH, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2007) 110 (11): 3024.

https://doi.org/10.1182/blood.V110.11.3024.3024

Published: 2007

Journal Articles

Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

Jia Ruan, MD, PhD, Morton Coleman, MD, Richard R. Furman, MD, Patricia Glynn, Maureen Joyce, Jamie Ketas, Ken Cheung, PhD, Sarah Church, Tsiporah Shore, MD, Eric Feldman, MD, Sarah Rutherford, Elizabeth Hyjek, MD, PhD, Amy Chadburn, MD, Shahin Rafii, MD, John P. Leonard, MD

Blood (2006) 108 (11): 2751.

https://doi.org/10.1182/blood.V108.11.2751.2751

Published: 2006

Journal Articles

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Brian A. Di Carlo, MD, Jessica L. Stern, Michael Schuster, MD, Tsiporah Shore, MD, John Harpel, MD, PhD, Roger Pearse, MD, PhD, Faiza Zafar, PA, Joanne Dymek, NP, Jessy Ryan, NP, David Jayabalan, MA, Selina Chen-Kiang, PhD, Scott Ely, MD, John P. Leonard, MD, Morton Coleman, MD, Ruben Niesvizky, MD

Blood (2006) 108 (11): 3538.

https://doi.org/10.1182/blood.V108.11.3538.3538

Published: 2006

Journal Articles

Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).

Gail J. Roboz, MD, Ellen K. Ritchie, MD, Michael W. Schuster, MD, Tsiporah Shore, MD, Tania J. Curcio, R.N., Sandra Allen-Bard, N.P., Juliette L. Provenzano, MS, Eric J. Feldman, MD

Blood (2005) 106 (11): 1856.

https://doi.org/10.1182/blood.V106.11.1856.1856

Published: 2005

NARROW

Ultimate Outcomes of Patients with Recurrent Diffuse Large B Cell Lymphoma Who Do Not Respond to Second-Line Chemotherapy

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

Ultimate Outcomes of Patients with Recurrent Diffuse Large B Cell Lymphoma Who Do Not Respond to Second-Line Chemotherapy

BiRD (Biaxin [clarithromycin]/Revlimid [lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma.

Cyclophosphamide Overcomes the Suppressive Effect of LenalidomideTherapy on Stem Cell Collection in Preparation for Autologous Stem Cell Transplantation for Multiple Myeloma.

Targeting Angiogenesis in Mantle Cell Lymphoma: Clinical Efficacy and Correlative Studies of a Phase II Trial of RT-PEPC (Rituximab, Thalidomide and Metronomic Oral Chemotherapy with Prednisone, Etoposide, Procarbazine and Cyclophosphamide) in Relapsed/Refractory Disease.

Breaking the Plateau Response in Myeloma: Preliminary Results of a Phase II Pilot Study of Sequential Bortezomib in Combination with Dexamethasone and Pegylated Liposomal Doxorubicin (DoVeD) in Patients No Longer Responsive to Standard Induction Regimens.

Gemtuzumab Ozogamicin Is an Acceptable Alternative to Anthracyclines in Combination with Standard Dose Infusional Cytarabine as Induction Therapy for Elderly Patients with Acute Myeloid Leukemia (AML).

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only